Review anchor
Penicillin-binding protein 1
SINGLE PROTEIN · Staphylococcus aureus
As of 2026-09-13
Evidence Snapshot
Penicillin-binding protein 1
CHEMBL4268
SINGLE PROTEIN
Staphylococcus aureus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Penicillin-binding protein 1 as ChEMBL target CHEMBL4268, mapped to UniProt Q53725. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4268
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q53725
Cell division protein FtsI (Peptidoglycan synthetase)
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Penicillin-binding protein 1 matters
Penicillin-binding protein 1 is reviewed as Cell division protein FtsI (Peptidoglycan synthetase) (UniProt Q53725); Penicillin-binding protein 1 shows approved-linked disease relevance led by bacteriemia. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 21 compounds, and 6 assays.
Protein context
Cell division protein FtsI (Peptidoglycan synthetase)
Cell division protein FtsI (Peptidoglycan synthetase) Sequence length is 744 aa.
Review this target as Penicillin-binding protein 1, mapped to UniProt Q53725. ChEMBL maps the protein component as Cell division protein FtsI (Peptidoglycan synthetase). Sequence length is 744 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q53725
Protein
Disease context
bacteriemia
Penicillin-binding protein 1 shows approved-linked disease relevance led by bacteriemia. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CEFTOBIPROLE MEDOCARIL SODIUM.
Start review with bacteriemia because it currently carries approved-linked support. Linked drugs include CEFTOBIPROLE MEDOCARIL SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 21 compounds, and 6 assays for this target. The dominant activity type is IC50.
Activity source · ChEMBL 36 via Core EngineSource Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Penicillin-binding protein 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q53725, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why bacteriemia is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
21
Total Compounds
6
Total Assays
0
Approved Drugs
IC50: 20.0
Activity Types
pChEMBL Activity Distribution
Source Header